The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
Introduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1...
| Autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad de Cantabria (UC) |
| Repositorio: | UCrea Repositorio Abierto de la Universidad de Cantabria |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unican.es:10902/39101 |
| Acceso en línea: | https://hdl.handle.net/10902/39101 |
| Access Level: | acceso abierto |
| Palabra clave: | Biomarkers Immunoglobulin A vasculitis (IgAV) NF-kappa B (NF-kB) NFKB1 NFKBIA |
| id |
ES_f8dbcd1a3848b47ecba01b4a250dcbb2 |
|---|---|
| oai_identifier_str |
oai:repositorio.unican.es:10902/39101 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitisBatista Liz, Joao CarlosSebastián Mora Gil, MaríaRenuncio García, MónicaLeonardo Cabello, María TeresaPeñalba Citores, Ana CristinaGabriel Odonnell, LigiaSánchez, Rafael GálvezMartín Penagos, LuisNarvaez, JavierSevilla Pérez, BelénRíos Fernández, RaquelCallejas Rubio, José LuisCaminal Montero, LuisCollado, PazPérez Venegas, José JavierRodríguez Valls, María JoséDe Árgila, DiegoQuiroga Colina, PatriciaVicente Rabaneda, Esther FranciscaOcejo-Vinyals, Javier GonzaloBiomarkersImmunoglobulin A vasculitis (IgAV)NF-kappa B (NF-kB)NFKB1NFKBIAIntroduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1 (encoding NF-kB1) and NFKBIA (encoding NF-kB inhibitor alpha) have been identified as risk loci for several immune-mediated diseases, but their role in IgAV remains unclear. This study aimed to determine whether NFKB1 and NFKBIA represent novel genetic risk factors for IgAV pathogenesis. Methods: The NFKB1 promoter variant −94 ins/del ATTG (rs28362491), six tag NFKB1 polymorphisms (rs77830930, rs1598856, rs7340881, rs4648055, rs4648090, and rs230547), and seven tag NFKBIA variants (rs3138055, rs696, rs1022714, rs2233419, rs2233415, rs1050851, and rs1957106) were genotyped in 343 Caucasian IgAV patients and 764 healthy, ethnically matched controls using TaqMan probes. Patients were stratified according to age at disease onset and the presence or absence of renal, articular, and gastrointestinal manifestations. Genotype, allele, and haplotype frequencies were compared between patients and controls, as well as across clinical subgroups. Results: No statistically significant differences were found in genotype or allele frequencies of NFKB1 or NFKBIA between IgAV patients and healthy controls. Likewise, haplotype frequencies of both genes were similar across groups. No associations were observed when patients were stratified by clinical features, including renal involvement, age at onset, or articular/gastrointestinal symptoms. Conclusion: Our findings do not support a major role for the NFKB1 or NFKBIA variants studied in IgAV susceptibility or severity. These results suggest that if NFkB signaling contributes to IgAV pathogenesis, it likely involves other biological mechanisms.The author(s) declare financial support was received for the research and/or publication of this article. This research was funded by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), grant numbers PI21/00042 and PI24/00382. JCBL. is a recipient of a PFIS program fellowship from the ISCIII, cofunded by the European Social Fund (‘Investing in your future’), grant number FI22/00020. VP-C received funding from IDIVAL, grant numbers NVAL23/02 and INNVAL24/10. RL-M is a recipient of a Miguel Servet type II program fellowship from the ISCIII, cofunded by ESF (“Investing in your future”), grant number CPII21/00004.Frontiers Research FoundationUniversidad de Cantabria20252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/39101Frontiers in Immunology, 2025, 16, 1692908reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/391012026-06-02T12:39:31Z |
| dc.title.none.fl_str_mv |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| title |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| spellingShingle |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis Batista Liz, Joao Carlos Biomarkers Immunoglobulin A vasculitis (IgAV) NF-kappa B (NF-kB) NFKB1 NFKBIA |
| title_short |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| title_full |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| title_fullStr |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| title_full_unstemmed |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| title_sort |
The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis |
| dc.creator.none.fl_str_mv |
Batista Liz, Joao Carlos Sebastián Mora Gil, María Renuncio García, Mónica Leonardo Cabello, María Teresa Peñalba Citores, Ana Cristina Gabriel Odonnell, Ligia Sánchez, Rafael Gálvez Martín Penagos, Luis Narvaez, Javier Sevilla Pérez, Belén Ríos Fernández, Raquel Callejas Rubio, José Luis Caminal Montero, Luis Collado, Paz Pérez Venegas, José Javier Rodríguez Valls, María José De Árgila, Diego Quiroga Colina, Patricia Vicente Rabaneda, Esther Francisca Ocejo-Vinyals, Javier Gonzalo |
| author |
Batista Liz, Joao Carlos |
| author_facet |
Batista Liz, Joao Carlos Sebastián Mora Gil, María Renuncio García, Mónica Leonardo Cabello, María Teresa Peñalba Citores, Ana Cristina Gabriel Odonnell, Ligia Sánchez, Rafael Gálvez Martín Penagos, Luis Narvaez, Javier Sevilla Pérez, Belén Ríos Fernández, Raquel Callejas Rubio, José Luis Caminal Montero, Luis Collado, Paz Pérez Venegas, José Javier Rodríguez Valls, María José De Árgila, Diego Quiroga Colina, Patricia Vicente Rabaneda, Esther Francisca Ocejo-Vinyals, Javier Gonzalo |
| author_role |
author |
| author2 |
Sebastián Mora Gil, María Renuncio García, Mónica Leonardo Cabello, María Teresa Peñalba Citores, Ana Cristina Gabriel Odonnell, Ligia Sánchez, Rafael Gálvez Martín Penagos, Luis Narvaez, Javier Sevilla Pérez, Belén Ríos Fernández, Raquel Callejas Rubio, José Luis Caminal Montero, Luis Collado, Paz Pérez Venegas, José Javier Rodríguez Valls, María José De Árgila, Diego Quiroga Colina, Patricia Vicente Rabaneda, Esther Francisca Ocejo-Vinyals, Javier Gonzalo |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universidad de Cantabria |
| dc.subject.none.fl_str_mv |
Biomarkers Immunoglobulin A vasculitis (IgAV) NF-kappa B (NF-kB) NFKB1 NFKBIA |
| topic |
Biomarkers Immunoglobulin A vasculitis (IgAV) NF-kappa B (NF-kB) NFKB1 NFKBIA |
| description |
Introduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1 (encoding NF-kB1) and NFKBIA (encoding NF-kB inhibitor alpha) have been identified as risk loci for several immune-mediated diseases, but their role in IgAV remains unclear. This study aimed to determine whether NFKB1 and NFKBIA represent novel genetic risk factors for IgAV pathogenesis. Methods: The NFKB1 promoter variant −94 ins/del ATTG (rs28362491), six tag NFKB1 polymorphisms (rs77830930, rs1598856, rs7340881, rs4648055, rs4648090, and rs230547), and seven tag NFKBIA variants (rs3138055, rs696, rs1022714, rs2233419, rs2233415, rs1050851, and rs1957106) were genotyped in 343 Caucasian IgAV patients and 764 healthy, ethnically matched controls using TaqMan probes. Patients were stratified according to age at disease onset and the presence or absence of renal, articular, and gastrointestinal manifestations. Genotype, allele, and haplotype frequencies were compared between patients and controls, as well as across clinical subgroups. Results: No statistically significant differences were found in genotype or allele frequencies of NFKB1 or NFKBIA between IgAV patients and healthy controls. Likewise, haplotype frequencies of both genes were similar across groups. No associations were observed when patients were stratified by clinical features, including renal involvement, age at onset, or articular/gastrointestinal symptoms. Conclusion: Our findings do not support a major role for the NFKB1 or NFKBIA variants studied in IgAV susceptibility or severity. These results suggest that if NFkB signaling contributes to IgAV pathogenesis, it likely involves other biological mechanisms. |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025 2025-01-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 NA http://purl.org/coar/version/c_be7fb7dd8ff6fe43 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10902/39101 |
| url |
https://hdl.handle.net/10902/39101 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Frontiers Research Foundation |
| publisher.none.fl_str_mv |
Frontiers Research Foundation |
| dc.source.none.fl_str_mv |
Frontiers in Immunology, 2025, 16, 1692908 reponame:UCrea Repositorio Abierto de la Universidad de Cantabria instname:Universidad de Cantabria (UC) |
| instname_str |
Universidad de Cantabria (UC) |
| reponame_str |
UCrea Repositorio Abierto de la Universidad de Cantabria |
| collection |
UCrea Repositorio Abierto de la Universidad de Cantabria |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869425041299472384 |
| score |
15,81155 |